ADC Therapeutics SA
corporate_fare Company Profile
ADC Therapeutics SA (NYSE:ADCT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for ADCT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ADCT spans 8-K, S-4, 10-Q, DEF 14A.
Recent high-impact activity:
- ADC Therapeutics Q3 Revenue Jumps to $21.0M, Cash Runway Extended Into 2029
- Q3 Revenue Jumps 33% to $21M as Restructuring Extends Cash Runway Into 2029
- ADC Therapeutics Reports 88.7% ORR in LOTIS-7 and Preliminary Q3 Revenue of $21M
- ADC Therapeutics Files S-4 for Switzerland-to-Delaware Redomiciliation, Shareholder Vote Required
- ADC Therapeutics Restructures: $86.6M PIPE, $70M Debt Paydown, HCR Royalty Rework
Financial Snapshot
Short Interest & Short Volume
6.66 days to coverFINRA reported short interest of 6,427,616 shares in ADCT as of the October 30, 2026 settlement, a 1.4% increase from the prior period — about 6.7 days to cover at its recent average daily volume. On November 20, 2026, 56.1% of ADCT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for ADCT, detected from its recent SEC filings · based on capital-structure filings through 2026-10-13.
$86.6M PIPE at Deep Discount · Massive Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →